Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

D’Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S. Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis. J Crohns Colitis. 2025 Jun 4;19(6):jjaf080. doi: 10.1093/ecco-jcc/jjaf080. | PMID: 40355364

This study reports the 12-week efficacy and safety results of deucravacitinib in patients with inflammatory bowel disease, evaluating data from three randomized phase 2 trials including Crohn’s disease and ulcerative colitis patients.

Key Learning Points

• •
  Deucravacitinib showed promising efficacy in reducing inflammatory bowel disease activity within 12 weeks.
• •
  Safety profile was consistent with previous studies and acceptable over the short-term follow-up period.